2023
DOI: 10.1016/j.eplepsyres.2022.107065
|View full text |Cite
|
Sign up to set email alerts
|

GRIN2A-related epilepsy and speech disorders: A comprehensive overview with a focus on the role of precision therapeutics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 82 publications
0
1
0
Order By: Relevance
“…Pathogenic variants of GRIN2A induce gains or losses of NMDAR function; possible therapies for the former are uncompetitive NMDAR antagonists (see, in particular, memantine), while a possible therapy for the latter is the NMDAR co-agonist serine. Precision therapies for GRIN2A-related disorders could benefit these patients [281].…”
Section: Etiopathogenetic Factors Of Csws (Including Eses and Lks)mentioning
confidence: 99%
“…Pathogenic variants of GRIN2A induce gains or losses of NMDAR function; possible therapies for the former are uncompetitive NMDAR antagonists (see, in particular, memantine), while a possible therapy for the latter is the NMDAR co-agonist serine. Precision therapies for GRIN2A-related disorders could benefit these patients [281].…”
Section: Etiopathogenetic Factors Of Csws (Including Eses and Lks)mentioning
confidence: 99%